603077.SS
603077.SS
CNE100001JM9
SICHUAN HEBANG BIOTECHNOLOGY CO
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 60/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±36.6% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.5x).

Beta (Market Relation)
0.51x
Defensive
Volatility (5Y p.a.)
36.6% p.a.
5-Year Horizon
Max Drawdown (5Y)
-64.6%
5-Year Horizon
Sharpe Ratio
-0.40
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -2.6%
3 Years 36.8% -37.5% -0.11 -1.6%
5 Years 36.6% -64.6% -0.4 -11.2%
10 Years 35.6% -66.0% -0.1 -0.9%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Strong cyclicality: The business model is sensitive to economic downturns.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (36.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -66.0% in the extended horizon.
ende